May 12, 2026
May 12, 2026
May 12, 2026
May 12, 2026
May 12, 2026
May 12, 2026
May 12, 2026
May 12, 2026
Moderna's pivot from 'vaccine' to 'individualized neoantigen therapy' is a strategic move to dodge skepticism. But can rebranding truly overcome public and regulatory hurdles?